Belzutifan/Lenvatinib Outperforms Cabozantinib After Checkpoint Inhibitors in Advanced Renal Cell Carcinoma - Summary - MDSpire
Clinical Guidelines
From the Journals

Belzutifan/Lenvatinib Outperforms Cabozantinib After Checkpoint Inhibitors in Advanced Renal Cell Carcinoma

At the first and second interim analyses of the phase III LITESPARK-011 trial, treatment with the novel first-in-class hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor belzutifan plus lenvatinib im...

Share

The phase III LITESPARK-011 trial results indicate that the combination of belzutifan, a first-in-class HIF-2α inhibitor, and lenvatinib significantly improves progression-free survival and shows a trend toward better overall survival compared to cabozantinib in patients with advanced clear cell renal cell carcinoma post anti–PD-(L)1 therapy. Conducted by Dr. Robert J. Motzer at Memorial Sloan Kettering Cancer Center, this trial is a pivotal study examining treatment options for this patient population that has limited options after immunotherapy failure.

Original Source(s)

Belzutifan/Lenvatinib Outperforms Cabozantinib After Checkpoint Inhibitors in Advanced Renal Cell Carcinoma

  • by Julia Cipriano

  • April 30, 2026

Related Content

What Is the Optimal Setting for T-DXd in Early Breast Cancer? Experts Differ

Trastuzumab deruxtecan (T-DXd) has claimed a large share of the HER2-positive breast cancer landscape, even finding room among tumors previously thought to be HER2-negative. The DESTINY series of tria...

Acupuncture for Nocturia in Survivors of Prostate Cancer

Guest Editor’s Note: Nocturia, waking up from sleep more than once to urinate, is prevalent in survivors of prostate cancer and is associated with a diminished quality of life and a higher mortality t...

Accelerating Biopharmaceutical Development with CE-MS

Microfluidic CE-MS interfaces simplifies and streamlines biotherapeutic characterization to reduce turnaround times in bioanalytical labs

  • April 30, 2026

  • 7 min